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sion as a major preoperative risk factor for mortality in AAD pts. Pts bearing severe
hypotension from the onset of symptoms to surgery have a worse mortality rate than
those that who do not (42.3% vs 13.5%, p<0.0001).
Conclusions: Our study provides information regarding the importance of preoperative
hemodynamic status, from symptom onset to surgery, as a predictor of mortality in AAD
pts. Knowledge about temporal variations of these parameters may help surgeons in
making treatment decisions among high-risk patients being considered for potentially
heroic surgical attempts.
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1047-177 Significant Lipid Changes in a Large-Scale Trial of 
Fenofibrate to Prevent Cardiovascular Disease in Type 2 
Diabetes
Anthony C. Keech, James D. Best, Russell S. Scott, Philip J. Barter, R. John Simes, Peta 
Forder, Marja-Riitta Taskinen, The FIELD Study Investigators, NHMRC Clinical Trials 
Centre, The University of Sydney, Sydney, Australia
Background: The Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) trial
is a randomized controlled trial designed to test the effects of a long-term increase in
high-density lipoprotein cholesterol (HDL-C) and decrease in triglycerides (TG) with
fenofibrate therapy on coronary heart disease (CHD) events and mortality in diabetes.
Methods: The FIELD trial included 9,795 type 2 diabetic patients (50-75 years; total cho-
lesterol 3.0-6.5 mmol/L), who received either micronized fenofibrate 200 mg or placebo
daily for > 5 years, and could start lipid-lowering therapy (including statin treatment) at
any time after randomization. The median follow-up is over 3.3 years, with an estimated
500 major coronary events (fatal CHD and nonfatal myocardial infarction) accruing in 5
years.
Results: Baseline characteristics. 
Fenofibrate (6 week run-in) reduced total cholesterol 10.4%, low-density lipoprotein cho-
lesterol 9.8%, and TG 25.2%, and increased HDL-C 6.5%. These changes reflect those
seen in the Veterans Affairs-HDL Intervention Trial (VA-HIT), in which gemfibrozil
reduced total cholesterol 4.0% and TG 31%, and increased HDL-C 6.0% after 12
months.
Conclusion: In the FIELD trial, the largest primary prevention study in type 2 diabetic
patients, fenofibrate therapy led to substantial beneficial changes in the diabetic lipid pro-
file, consistent with those seen in the VA-HIT. The FIELD trial will clarify the benefits of
fibrate therapy on lipid modification and CHD prevention in type 2 diabetes.
1047-178 Low-Density Lipoprotein Subfractions in a Random 
Sample of Children and Adolescents
Karen Olson, Bryan Hendricks, Kirk Jenkins, Sharon Fox, Mary Roth, Patrick Hughes, 
David K. Murdock, Cardiovascular Research and Education Foundation, Inc, Wausau, 
WI, Community Health Care/Wausau Health Foundation, Wausau, WI
Background: The Wausau SCHOOL Project is a community-based effort to assess the
frequency of cardiovascular risk factors in students in the Wausau School District. Lipo-
protein sub-fraction studies in adults have demonstrated that a preponderance of small
dense LDL particles (Pattern B) is associated with obesity, decreased HDL levels, insulin
resistance (IR) and increased risk of heart disease. Limited information is available on
lipoprotein sub-fractions in children and young adults. Objective: Describe the frequency
of pattern B (PB) in students and assess its relationship to age and sex adjusted body
mass index (BMI), IR, HDL and triglyceride levels. Methods: Lipid profiles and lipopro-
tein sub-fractions were measured in 586 randomly selected students from grades 2, 5, 8
and 11, using a magnetic resonance method (LipoScience®). PB was defined as mean
particle size <20.6nm. IR was assessed in 2nd and 11th graders by the homeostasis
model assessment of insulin resistance (HOMA-IR). Overweight was defined as age and
sex adjusted BMI > 85th centile based on 2000 CDC norms. Results: The incidence of
PB increased nearly 4-fold across the 4 tested grades (2.2% in 2nd grade, 5.6% in 5th
grade, 4.9% in 8th grade and 8.7% in 11th grade). Those demonstrating PB had signifi-
cantly lower HDL, higher triglycerides, LDL particle number, HOMA-IR and BMI, but not
higher total or LDL cholesterol levels. Students with PB had an average BMI at the 81.6
centile of the CDC norms, whereas those with non-PB were at the 63.9rd centile. Nearly
32% were overweight, ranging from 27.6% (2nd grade) to 37.4% (8th grade). Conclu-
sions: The frequency of PB increases with age. As seen in adults, PB in youth is associ-
ated with IR, higher triglycerides, decreased HDL levels and high BMI.
1047-179 Serum Triglycerides and the Risk of Cardiovascular 
Disease in the Asia Pacific Region: An Individual 
Participant Data Meta-Analysis of Cohort Studies 
Including 96,130 Individuals
Anushka Patel, Mark Woodward, Federica Barzi, Dongfeng Gu, Hirotsugu Ueshima, for 
the Asia Pacific Cohort Studies Collaboration, Institute for International Health, University 
of Sydney, Sydney, Australia
Background: The importance of serum triglyceride levels as an independent risk factor
for cardiovascular diseases is controversial.
Methods: We performed an individual participant data meta-analysis of prospective
studies conducted in the Asia-Pacific region. Cox models were applied to the combined
data from 26 studies to estimate the overall and region-, sex-, and age-specific hazard
ratios for major cardiovascular diseases by fifths of triglyceride values.
Results: During 795,929 person-years of follow-up among 96,130 individuals, 638
deaths due to coronary heart disease and 667 stroke deaths were recorded. After adjust-
ment for major cardiovascular risk factors and correction for regression dilution, each 1
mmol/L higher level of usual triglyceride level was associated with a 34% (95% CI 14-
58%) greater risk of coronary death. There was clear evidence of an association between
triglycerides and ischaemic stroke risk, but not with risk of haemorrhagic stroke. The
association between triglycerides and coronary death was similar when stratified by age
or sex, but there was a trend towards a stronger association in Australia / New Zealand
compared with Asian cohorts (hazard ratio for 1 mmol/L higher usual triglyceride level
1.54 [95%CI:1.26-1.89] vs. 1.12[95%CI:0.86-1.45], p=0.06).
Conclusions: In the largest study examining this question to date, triglycerides were
found to be an independent risk factor for cardiovascular diseases in the Asia-Pacific
region. The value of incorporating triglycerides into clinical algorithms for prediction of
individual risk of cardiovascular disease and the specific role of therapy aimed at lower-
ing serum triglyceride levels should be further investigated. 
Table: Pre-operative Hemodynamic Status of Surgical Type A Acute Aortic Dissection Patients
Variables Overall 
(n=526)
Survived 
(n=394)
Dead 
(n=132)
p Value
BLOOD PRESSURE AT 
PRESENTATION
Hypertension (SBP >
150 mmHg)
160 (32.4) 128 (34.2) 32 (26.7) 0.124
Normotension (SBP 100-149 
mmHg)
213 (42.9) 176 (46.9) 37 (30.6) 0.002
Hypotension (SBP < 100 mmHg) 88 (17.6) 50 (13.3) 38 (30.4) <0.0001
Shock or tamponade (SBP < 80 
mmHg)
82 (16.1) 47 (12.3) 35 (27.6) <0.0001
BLOOD PRESSURE AFTER 
HOSPITALIZATION
In-hospital pre-op. hypotension 
(SBP < 100 mmHg)
123 (24.7) 73 (19.5) 50 (40.7) <0.0001
Hypotension from onset to surgery 213 (40.6) 123 (31.3) 90 (68.2) <0.0001
HEMODYNAMICS AT SURGERY
Hypotension/Shock at surgery 153 (31.0) 79 (21.4) 74 (59.2) <0.001
Normotension at surgery 262 (53.9) 219 (60.5) 43 (34.7) <0.001
LV dysfunction at surgery 63 (13.0) 34 (9.3) 29 (24.2) <0.001
RV dysfunction at surgery 31 (6.4) 10 (2.8) 21 (17.5) <0.001
Characteristic (% or median) Males Females Total
Age >65 years 42% 38% 41%
Current smoker 10% 8% 9%
BMI >30 kg/m2 42% 60% 48%
Diabetes duration (years) 7.2 6.7 7.0
History of hypertension 52% 64% 57%
Prior cardiovascular disease 20% 15% 18%
Receiving insulin 14% 13% 13%
Total cholesterol (mmol/L) 5.0 5.3 5.1
HDL-C (mmol/L) 1.0 1.2 1.1
TG (mmol/L) 1.7 1.8 1.7
Urinary albumin >20 mg/L 36% 27% 33%
HbA1c 6.9% 6.9% 6.9%
